Zolmitriptan is a synthetic tryptamine derivative that acts as an agonist at 5-HT1B/1D receptors, binding primarily in the ventral palladium, external globus pallidus, substantia nigra, visual cortex, and nucleus accumbens. This compound displays anti-inflammatory, anti-migraine, and neuroprotective activities. Zolmitriptan treats migraines, inhibiting dilation and inflammation of cranial vessels. This compound also alters NMDA receptor-evoked cGMP and NO signaling. In addition to its modulation of neurotransmitter levels, zolmitriptan inhibits action potential discharge of trigeminal neurons, suggesting antinociceptive activity as well.